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The opposite interplay between peroxisome proliferator-activated receptor gamma 
(PPAR gamma) and Wnt/beta-catenin signaling has led to the categorization of neurode-
generative diseases (NDs) as either NDs in which PPAR gamma is downregulated while 
the canonical Wnt/beta-catenin pathway is upregulated [amyotrophic lateral sclerosis 
(ALS), Parkinson’s disease, Huntington’s disease, multiple sclerosis, Friedreich’s ataxia] 
or NDs in which PPAR gamma is upregulated while the canonical Wnt/beta-catenin 
signaling is downregulated (bipolar disorder, schizophrenia, Alzheimer’s disease). ALS, 
a common adult-onset debilitating ND, is characterized by a chronic and progressive 
degeneration of upper and lower motor neurons resulting in muscular atrophy, paralysis, 
and ultimately death. The intent of this review is to provide an analysis of the integration 
of these two opposed systems, i.e., canonical Wnt/beta-catenin and PPAR gamma, in 
ALS. Understanding this integration may aid in the development of novel ALS therapies. 
Although the canonical Wnt/beta-catenin pathway is upregulated in ALS, riluzole, an 
enhancer of the canonical Wnt signaling, is classically prescribed in this disease in 
humans. However, studies carried out on ALS transgenic mice have shown beneficial 
effects after treatment by PPAR gamma agonists partly due to their anti-inflammatory 
effects.
Keywords: amyotrophic lateral sclerosis, wnt/beta-catenin, PPAR gamma, lithium, riluzole, bexarotene, tretinoin, 
retinoid acid 
inTRODUCTiOn
Neurodegenerative diseases (NDs) are frequent and often present a bad prognosis. Both peroxisome 
proliferator-activated receptor (PPAR) gamma and the canonical Wnt/beta-catenin pathway play 
a key role in the pathophysiology of several NDs. The opposite interaction between PPAR gamma 
and the canonical Wnt/beta-catenin pathway has been reported in numerous studies (1–7). Certain 
NDs can be divided into two categories (8). On the one hand, there are NDs in which PPAR gamma 
is upregulated while the Wnt/beta-catenin pathway is downregulated, such as in bipolar disorder, 
schizophrenia, and Alzheimer’s disease. On the other hand, there are NDs in which PPAR gamma is 
downregulated while the Wnt/beta-catenin pathway is upregulated, such as in amyotrophic lateral 
sclerosis (ALS), Huntington’s disease, Parkinson’s disease, multiple sclerosis, and Friedreich’s ataxia. 
PPAR gamma agonists could exert protective effects in several NDs. They induce beneficial effects in 
FiGURe 1 | A schematic model of the canonical wnt/beta-catenin 
pathway in ALS. In ALS, the canonical Wnt/beta-catenin pathway is 
upregulated (“on state”). Binding of Wnt to Fzd leads to activation of Dsh, 
which recruits the destruction complex to the plasma membrane. AXIN binds 
to the cytoplasmic tail of LRP5/6. Wnt also binds LRP5/6. This initiates LRP 
phosphorylation and Dsh-mediated Frizzled internalization. Activation of Dsh 
leads to the inhibition of GSK-3beta, which further reduces the 
phosphorylation and degradation of beta-catenin. The beta-catenin 
degradation complex AXIN/APC/GSK-3beta is inactivated with the 
recruitment of AXIN to the plasma membrane. Beta-catenin phosphorylation 
is inhibited. Then, beta-catenin accumulates into the cytosol and translocates 
to the nucleus to bind TCF–LEF co-transcription factors. This induces the 
canonical Wnt-response gene transcription (c-Myc, cyclin D, etc.). 
Abbreviations: APC, adenomatous polyposis coli; Dsh, Dishevelled; Fzd, 
Frizzled; GSK-3beta, glycogen synthase kinase-3beta; LRP5/6, low density 
lipoprotein receptor-related protein 5/6; TCF/LEF, T-cell factor/lymphoid 
enhancer factor; Wnt target genes: c-Myc, cyclin D; Wnt*, Wnt with ligands.
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ALS neurons of transgenic mice (9–12). Moreover, PPAR gamma 
coactivator-1alpha (PGC-1alpha) protects neurons and slows 
down the disease progression in ALS double transgenic mice 
(13, 14). PPAR gamma signaling may represent a therapeutic 
target in human ALS. Although the canonical Wnt/beta-catenin 
pathway is upregulated in ALS (15–18), riluzole, an enhancer of 
this system (19) represents a classically prescribed treatment of 
this disease in humans.
AMYOTROPHiC LATeRAL SCLeROSiS
Amyotrophic lateral sclerosis has been first described by J. M. 
Charcot in 1869. ALS, a fatal neurodegenerative disorder, is 
characterized by a chronic and progressive degeneration of the 
upper and lower motor neurons. This results in muscular atrophy, 
paralysis, and ultimately death. ALS is a common adult-onset 
debilitating ND. Its prevalence is about 5 per 100,000 individuals. 
Today, the pathophysiology of ALS in humans is not fully eluci-
dated and is particularly complex partly due to various intercon-
nected pathological mechanisms (20). 82% of ALS is sporadic. 
The most frequent mutations in familial ALS (FALS) or inherited 
are found in the SOD1 gene (Cu, Zn superoxide dismutase). FALS 
presents glutamate toxicity, mitochondrial dysfunction, and 
axonal transport defects (20). Many animal studies have used the 
mutant SOD1 transgenic mice (21). This model is reminiscent of 
the human ALS phenotype by developing a progressive motor 
neuron degeneration (22). The human sporadic ALS differs little 
clinically from SOD1-related FALS. Both forms induce motor 
neuron degeneration, paralysis, and death within 3–5  years 
from the appearance of the first symptoms. No  pharmacological 
therapy can really stop the progression of ALS. Nevertheless 
riluzole is approved for the treatment of ALS patients although 
the benefits of this drug remain marginal (23–26).
PPAR GAMMA
Peroxisome proliferator-activated receptor gamma, a ligand-
activated transcriptional factor, belongs to the nuclear hormone 
receptor superfamily. All PPARs heterodimerize with the retinoid 
X receptor (RXR), and they bind to peroxisome proliferator 
response elements, which are specific regions on the DNA of 
target genes. Naturally occurring agents directly activate PPAR 
gamma. PPAR gamma is expressed in various cell types, such as 
adipose tissue, immune cells, and brain cells, including astrocytes 
and microglia. This contributes to the anti-inflammatory response 
in the central nervous system (CNS) (27, 28). PPAR gamma 
regulates the expression of numerous genes implied in various 
cellular mechanisms, such as regulation of glucose homeostasis, 
insulin sensitivity, lipid metabolism, immune response, inflam-
mation, and cell fate (29, 30). PPAR gamma is involved in several 
pathological states, such as diabetes, obesity, atherosclerosis, and 
cancer. PPAR gamma agonists, thiazolidinediones (TZDs), are 
insulin-sensitizing drugs, and certain TZDs have been used for 
treating type 2 diabetes. PPAR gamma diminishes inflammatory 
processes in many tissues. Moreover, PPAR gamma is a peripheral 
regulator of cardiovascular rhythms and controls circadian varia-
tions in blood pressure and heart rate through BMAL1 (31, 32). 
The role of PPAR gamma in neurodegeneration is well established 
(33). PPAR gamma agonists have been shown to be beneficial in 
several NDs, such as stroke, Alzheimer’s disease, ALS, Parkinson’s 
disease, Huntington’s disease, multiple sclerosis. PPAR gamma 
induces both neuroprotective and anti-inflammatory effects (27, 
28). Astrocytic GLT1/EAAT2 gene, a target of PPAR gamma, 
induces neuroprotection by increasing glutamate uptake (34).
CAnOniCAL wnt/BeTA-CATenin 
PATHwAY
Canonical Wnt/beta-catenin signaling plays a key role in embry-
onic development, cell migration, cell fate, and carcinogenesis 
(35, 36). Activation of the canonical Wnt pathway by Wnt ligands 
leads to increase the cytoplasmic beta-catenin level. Beta-
catenin subsequently translocates to the nucleus and activates 
beta-catenin-specific gene transcription (1, 37) (Figure  1). In 
the absence of Wnt ligand, beta-catenin is recruited into the 
destruction complex that contains adenomatous polyposis coli 
(APC), Axin, and glycogen synthase kinase-3beta (GSK-3beta), 
which induces phosphorylation of beta-catenin, thus targeting it 
for ubiquitination and proteasomal degradation (Figure  2). In 
the presence of Wnt ligand, the binding of Wnt to Frizzled (Fzd) 
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activates Dishevelled (Dsh). Dsh recruits Axin, which binds to 
the low density lipoprotein-receptor-related proteins (LRP5–6). 
Activation of Dsh inhibits GSK-3beta. This reduces phosphoryla-
tion and degradation of beta-catenin. The non-phosphorylated 
beta-catenin translocates to the nucleus and binds to T-cell/
lymphoid-enhancing binding (TCF/LEF) transcription factors. 
This activates numerous target genes, including c-myc, cyclin D1, 
Axin-2, CD44, Cox2, and PPAR beta/delta (38, 39).
OPPOSiTe inTeRPLAY BeTween PPAR 
GAMMA AnD CAnOniCAL  
wnt/BeTA-CATenin PATHwAY
PPAR Gamma Activation induces 
Repression of the Beta-Catenin Pathway
Several studies have shown the opposite interaction between 
beta-catenin and PPAR gamma (1, 5, 40). The TZDs troglitazone, 
rosiglitazone, pioglitazone, and a non-TZD PPAR gamma activa-
tor GW1929 inhibit the transcription of beta-catenin (2, 3, 5, 6). 
Opposite interaction between PPAR gamma and beta-catenin 
involves the TCF/LEF factor-binding domain of beta-catenin 
and a catenin-binding domain of PPAR gamma (3). The antago-
nism between the beta-catenin pathway and PPAR gamma has 
been reported in various cell types, such as adipocytes (2) and 
 hepatocytes (6). PPAR gamma suppresses the Wnt/beta-catenin 
pathway during adipogenesis (5). Conversely, activation of the 
canonical Wnt/beta-catenin pathway inhibits PPAR gamma 
expression (7).
Deactivation of the wnt/Beta-Catenin 
Pathway induces Activation of PPAR 
Gamma
Inhibition of Wnt/beta-catenin pathway leads to increase the 
transcription of PPAR gamma (1). In preadipocytes, prevention 
of the Wnt pathway by overexpression of Axin induces dif-
ferentiation into adipocytes. The canonical Wnt/beta-catenin/
PPAR gamma system regulates the molecular switching of 
adipogenesis versus osteablastogenesis. The adipogenic pathway 
implies inhibition of Wnt signaling, leading to degradation of 
beta-catenin. This results in transcription of PPAR gamma, which 
initiates adipogenesis (7). Deactivation of the canonical Wnt/
beta-catenin pathway and activation of PPAR gamma are also 
observed in arrhythmogenic right ventricular cardiomyopathy 
(ARVC) (1, 41). The suppression of canonical Wnt/beta-catenin 
signaling by plakoglobin (PG), i.e., gamma-catenin, recapitulates 
the phenotype of ARVC (1). The desmosomal PG has structural 
and functional similarities to beta-catenin (42). Gamma-catenin 
competes with beta-catenin through TCF/LEF transcription fac-
tors (43, 44). After competition with beta-catenin, gamma-catenin 
inhibits the canonical Wnt/beta-catenin-TCF/LEF pathway. This 
leads to enhance adipogenesis and fibrogenesis, as it is observed 
in human ARVC (1, 41, 45).
ALS AnD PPAR GAMMA
Neuroinflammation is commonly reported in NDs and particu-
larly in ALS. PPAR gamma is a regulator of neuroinflammation 
and possibly represents a target for new therapeutic strategies. 
Beneficial effects induced by PPAR gamma agonists, partly due to 
their anti-inflammatory effects, have been observed in NDs. PPAR 
gamma inhibits NF-kappa B-mediated inflammatory signaling 
(46, 47). In ALS transgenic mice, beneficial effects of pioglita-
zone have been mainly ascribed to its anti-inflammatory activity. 
PPAR gamma agonists reduce neuropathological damages caused 
by inflammation in ALS (11). The involvement of PPAR gamma 
in ALS progression has been demonstrated in hSOD1G93A mice 
using pioglitazone. Pioglitazone minimizes ALS-like symptoms 
(12) and increases survival in ALS transgenic mouse model 
(11). Pioglitazone-treated SOD1-G93A transgenic mice exhibit 
a delayed onset of the disease and survive significantly longer 
than non-treated transgenic mice. Pioglitazone induces neuro-
protection in motor neurons of the spinal cord. The median fiber 
diameter of the quadriceps muscle is preserved. This indicates a 
morphological and functional protection of motor neurons due 
to pioglitazone (12). In neuron-specific PPAR gamma knockout 
mice and in response to middle cerebral artery occlusion, sig-
nificant brain damages have been reported (48). Moreover, there 
is a reduced expression of certain genes, including SOD1 and 
 glutathione S-transferase. Thus, in normal neurons, PPAR gamma 
FiGURe 2 | A potential canonical wnt/beta-catenin pathway in ALS 
treated by PPAR gamma agonists. In the presence of PPAR gamma 
agonists, the “on state” of canonical Wnt/beta-catenin pathway may be 
interrupted at two potential levels. Firstly, via a hypothetical action of PPAR 
gamma* on APC. Inactivation of the destruction complex AXIN/APC/
GSK-3beta is suppressed. Beta-catenin is phosphorylated by GSK-3beta. 
Thus, APC and AXIN complex with GSK-3beta and beta-catenin to enhance 
the destruction process of beta-catenin into the proteasome. Phosphorylated 
beta-catenin is recognized by an ubiquitin ligase, ubiquinated and degraded 
into the proteasome. The canonical Wnt pathway is in “off state.” Second, 
PPAR gamma can inhibit the beta-catenin/TCF/LEF complex into the 
nucleus, thus inhibiting the transcription of canonical Wnt target genes. 
Abbreviations: APC, adenomatous polyposis coli; Dsh, Dishevelled; Fzd, 
Frizzled; GSK-3beta, glycogen synthase kinase-3beta; LRP5/6, low density 
lipoprotein receptor-related protein 5/6; PPAR gamma*, PPAR gamma 
activated by agonists; TCF/LEF, T-cell factor/lymphoid enhancer factor; 
canonical Wnt target genes: c-Myc, cyclin D, etc.
4Lecarpentier and Vallée Wnt/Beta-Catenin and PPAR-Gamma in ALS
Frontiers in Neurology | www.frontiersin.org June 2016 | Volume 7 | Article 100
is expressed and plays an important protective role. In addition 
to their anti-inflammatory effects, PPAR gamma agonists appear 
to be useful in neuroprotection. PPAR gamma activation induces 
neuroprotective effects in a Drosophila model of ALS, which reca-
pitulates several aspects of the ALS phenotype (10). In a phase II 
double-blind controlled clinical trial, pioglitazone, in combina-
tion with riluzole, does not increase survival in ALS patients (49). 
The absence of beneficial effects in this trial might be partly due 
to the fact that riluzole activates the canonical Wnt/beta-catenin 
signaling in neuronal cells, as it will be discussed below (19). 
Moreover, pioglitazone is not a selective PPAR gamma agonist 
and belongs to the dual PPAR alpha/gamma agonists. Several 
studies have revealed a potential risk of bladder cancer in diabetic 
patients treated with pioglitazone, such as to call into question the 
benefit/risk ratio of this PPAR agonist (50). To highlight PPAR 
transcriptional activity, genetically engineered mice (PPRE-Luc 
mice) have been bred with the hSOD1G93AALS mouse (51). In the 
PPRE-Luc± hSOD1G93A± double transgenic mice, PPAR gamma 
transcriptional activity increases in the spinal cord (9). PPAR 
gamma controls natural protective mechanisms against lipid 
peroxidation. This effect is correlated with the upregulation of 
lipid detoxification enzymes, such as glutathione S-transferase 
and alpha-2 lipoprotein lipase. These enzymes are implied in 
scavenging lipid peroxidation by-products.
ALS AnD PPAR GAMMA  
COACTivATOR-1 ALPHA
Peroxisome proliferator-activated receptor gamma coactivator-
1alpha, a transcriptional coactivator working together with 
PPAR gamma, plays an important role in numerous NDs (33). 
Increase in expression of PGC-1alpha in transgenic SOD1-G93A 
mice prevents neuronal cell death (52). SOD1-G93A mice present 
mitochondrial abnormalities in motor neurons of the spinal 
cord, and PGC-1alpha induces neuroprotection. Expression of 
PGC-1alpha reduces motor neuron degeneration in SOD1-G93A 
transgenic mice (13, 14). In PGC-1alpha transgenic mice crossed 
with SOD1 mutant G93A mice, there is a neuroprotection, and 
the progression of the disease is significantly slowed (13). Motor 
function and survival are improved by using a double transgenic 
mouse model where PGC-1alpha is overexpressed in a SOD1 
transgenic mouse (14). In this double transgenic mouse model, 
there are decreased weight loss, improved motor performance, 
slowed disease progression, and reduced motor neuronal death. 
In a mouse model of inherited ALS, increased PGC-1alpha 
activity sustains mitochondrial biogenesis and muscle function 
without extending survival (53).
ALS, PPAR GAMMA, ReTinOiD X 
ReCePTOR, AnD ReTinOiC ACiD
Peroxisome proliferator-activated receptor and RXR receptor 
form heterodimers to become functional. There is a convergence 
of the 9-cis retinoic acid and PPAR pathways through heterodi-
mer formation of the two receptors (54). Retinoid signaling is 
important in the development of the CNS and contributes to 
regenerative processes that occur after injury. In ALS, the retinoid 
signaling is involved in gene expression in the spinal cord (55). 
Abnormalities of the anaplastic lymphoma kinase (ALK) gene 
are associated with sporadic ALS. Reduced ALK mRNA levels 
have been reported in ALS patients (56). Midkine (MK), a ligand 
for ALK, is decreased in patients with sporadic ALS (57). MK 
expression is induced by the retinoic acid signaling. Moreover, 
MK activates ALK. Retinoic acid gene improves survival in the 
ALS SOD1-G93A transgenic mice (58). In ALS patients treated 
with tretinoin (i.e., retinoic acid), pioglitazone combined with 
riluzole has demonstrated no slowing on the disease progression 
(59). This might be partly explained by the fact that riluzole is 
an enhancer of the canonical Wnt pathway, as reported below. 
Bexarotene (Bxt), a highly selective RXR agonist, induces neuro-
protective effect in the SOD1G93A mouse model of ALS (60). Bxt 
significantly delays the early motor neuron degeneration in ALS 
transgenic mice and partially preserves the spinal motor neuron 
loss. Bxt ameliorates the loss of body weight and increases mouse 
survival up to 30% of the symptomatic period. Bxt preserves the 
neuromuscular function.
ALS AnD CAnOniCAL  
wnt/BeTA-CATenin PATHwAY
The canonical Wnt/beta-catenin signaling is involved in numer-
ous NDs, particularly in ALS. Many studies have shown that this 
pathway is upregulated in motor neurons of ALS mouse model 
(15–18). In the spinal cord of SOD1-G93A ALS transgenic mice, 
mRNAs and proteins of both Wnt2 and Wnt7a are upregulated 
(16). Activation of the Wnt signaling inhibits the GSK-3beta 
activity. In the spinal cord of these mice, mRNAs and proteins 
of both Wnt3a and Cyclin D1 are upregulated (15). Beta-catenin 
translocates to the nucleus and subsequently activates transcrip-
tion of the target gene Cyclin D1. Increase in Wnt5a and Fzd2 
expression in the spinal cord of SOD1-G93A ALS transgenic 
mice, SOD1-G93A transfected NSC-34 cells, and primary cul-
tures of astrocytes from SOD1-G93A transgenic mice have been 
shown to be changed (17). In the spinal cords of SOD1-G93A ALS 
transgenic mice, expression of Wnt1 and Fzd1 is increased (18).
ALS, RiLUZOLe, AnD LiTHiUM
No really efficient treatment exists for ALS (61, 62). However, 
riluzole is approved for the treatment of ALS in most countries. 
This is based on the results supporting a role of glutamate toxic-
ity in ALS. Riluzole has numerous pharmacological properties, 
i.e., presynaptic inhibition of the glutamate release, inhibition of 
G-protein-dependent processes, blockade of the voltage-gated 
sodium channel, and modulation of N-methyl-d-aspartate iono-
tropic receptor (61). Two trials (23, 24) have shown a prolonga-
tion of median survival by 2–3 months by using riluzole in human 
ALS. Two other studies have led to similar conclusions (25, 26). 
Interestingly, riluzole has been shown to be an enhancer of the 
Wnt/β-catenin signaling in melanoma (19). Treating melanoma 
cells with riluzole in vitro enhances the ability of Wnt3A to regu-
late gene expression and decrease cell proliferation. Importantly, 
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riluzole also enhances the Wnt/beta-catenin pathway in both 
HT22 neuronal cells and adult hippocampal progenitor cells 
(19). As the Wnt/beta-catenin pathway is upregulated, at least 
in genetic ALS mice (15–18), this might partly explain the poor 
results reported in trials testing riluzole in ALS (23–26). The GSK-
3beta-inhibitor lithium, an activator of the canonical Wnt/beta-
catenin signaling (63–65), has also been evaluated as a treatment 
for ALS (66). Surprisingly, in ALS patients treated with lithium, 
the disease progression appears to be markedly attenuated. In 
a parallel study on the genetic SOD1-G93A mouse ALS animal 
model, lithium induces a marked neuroprotection, delaying 
disease onset and duration and increasing the life span. Lithium 
is logically used for the treatment of bipolar disorder in which 
the Wnt/beta-catenin signaling is downregulated (67, 68). Thus, 
riluzole reduces symptoms of obsessive–compulsive disorder, 
unipolar and bipolar depression, and generalized anxiety disor-
der (69). This is expected because the Wnt/beta-catenin pathway 
is downregulated in bipolar syndrome and because riluzole, like 
lithium, are enhancers of the Wnt/β-catenin signaling (19).
COnCLUSiOn
Peroxisome proliferator-activated receptor gamma agonists rep-
resent promising therapeutics for certain NDs, such as ALS. PPAR 
gamma agonists appear to be beneficial in several ALS transgenic 
animal models partly due to their anti-inflammatory properties. 
Moreover, PPAR gamma activation induces repression of the 
beta-catenin pathway (2, 3, 5, 6). This represents the rationale for 
the use of PPAR gamma agonists in case of downregulation of 
PPAR gamma and upregulation of the Wnt/beta-catenin pathway, 
such as in ALS. New PPAR gamma agonists, specific and devoid of 
adverse side effects, might represent a new therapeutic approach 
for the treatment of ASL. PPAR gamma agonists increase survival 
in ALS transgenic mice and minimize neuroinflammation. Rather 
than stimulation of the canonical Wnt/beta-catenin pathway by 
riluzole administration, inhibition of this system might also 
represent a therapeutic approach in ALS.
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